H.C. Wainwright positive on Aprea (APRE) as APR-1051 shows 50% lesion reduction in endometrial cancer
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $4.00 price target on Aprea (NASDAQ: APRE)The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
